The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neo-adjuvant PARP inhibition prior to prostatectomy: A phase II biomarker-driven trial for men with high-risk, localized prostate cancer and alterations in DNA repair genes.
 
Marc Dall'era
Research Funding - Janssen
Expert Testimony - Sanofi
 
John McPherson
No Relationships to Disclose
 
Christopher P. Evans
Stock and Other Ownership Interests - Exelixis
Consulting or Advisory Role - Astellas Pharma; Pfizer
Speakers' Bureau - Janssen Biotech; Myovant Sciences; Pfizer
Research Funding - Anchiano (Inst); Astellas Pharma (Inst); Janssen Research & Development (Inst); Pfizer (Inst)
 
Mamta Parikh
Consulting or Advisory Role - AstraZeneca; Exelixis; OncoCyte; Seagen
Research Funding - Karyopharm Therapeutics
 
Rashmi Verma
No Relationships to Disclose
 
Primo N Lara
Consulting or Advisory Role - Calithera Biosciences (Inst); Janssen
Research Funding - Janssen Biotech (Inst); Taiho Pharmaceutical (Inst)